ATTO · Insider Trading
Attovia Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by ATTO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-08 | Steven Chan | Chief Financial Officer | A | +140,000 deriv. | — |
| 2026-10-08 | Tao Fu | President and CEO | A | +538,300 deriv. | — |
| 2026-08-28 | Colin Walsh | Director | MIXED | +2,914,825 | +$8.03M |
| 2026-08-28 | GOLDMAN SACHS GROUP INC | — | MIXED | +23,318,600 | +$64.27M |
| 2026-08-13 | Colin Walsh | Director | MIXED | +2,914,825 | +$8.03M |
| 2026-08-13 | West Street Life Sciences I, L.P. | — | MIXED | +23,318,600 | +$64.27M |
| 2026-08-10 | David Kroin | 10%+ Owner | C | +5,871,414 | — |
| 2026-08-10 | venBio Global Strategic Fund IV, L.P. | 10%+ Owner | MIXED | +4,181,367 | +$6.50M |
| 2026-08-07 | Sanofi | 10%+ Owner | MIXED | +1,082,855 | +$5.10M |
| 2026-08-07 | Redmile Group, LLC | 10%+ Owner | MIXED | +4,148,562 | +$30.60M |
| 2026-08-07 | Sanofi | 10%+ Owner | MIXED | +1,082,855 | +$5.10M |
| 2026-08-07 | Jeremy Green | 10%+ Owner | MIXED | +4,148,562 | +$30.60M |
| 2026-08-06 | Attovia Therapeutics, Inc. | Chief Financial Officer | A | +140,000 deriv. | — |
| 2026-08-06 | Attovia Therapeutics, Inc. | President and CEO | A | +538,300 deriv. | — |
| 2026-08-06 | Mitchell Gold | Director | A | +27,000 deriv. | — |
| 2026-08-06 | Hubert Chen | Chief Medical Officer | A | +140,000 deriv. | — |
| 2026-08-06 | Petter Veiby | Chief Scientific Officer | A | +140,000 deriv. | — |
| 2026-08-06 | Zaneta Odrowaz | Chief Business Officer | A | +140,000 deriv. | — |
| 2026-08-06 | FHMLS XI, L.L.C. | 10%+ Owner | MIXED | +18,236,592 | +$30.00M |
| 2026-08-06 | Angie You | Director | A | +27,000 deriv. | — |
| 2026-08-06 | Attovia Therapeutics, Inc. | Chief Financial Officer | A | +140,000 deriv. | — |
| 2026-08-06 | Mitchell Gold | Director | A | +27,000 deriv. | — |
| 2026-08-06 | Zaneta Odrowaz | Chief Business Officer | A | +140,000 deriv. | — |
| 2026-08-06 | Hubert Chen | Chief Medical Officer | A | +140,000 deriv. | — |
| 2026-08-06 | Attovia Therapeutics, Inc. | President and CEO | A | +538,300 deriv. | — |
| 2026-08-06 | Petter Veiby | Chief Scientific Officer | A | +140,000 deriv. | — |
| 2026-08-06 | Angie You | Director | A | +27,000 deriv. | — |
| 2026-08-06 | Frazier Life Sciences XI, L.P. | 10%+ Owner | MIXED | +18,236,592 | +$30.00M |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| FHMLS XI, L.L.C. | 10%+ Owner | 5,565,978 | $77.26M |
| venBio Global Strategic Fund IV, L.P. | 10%+ Owner | 3,133,868 | $43.50M |
| Redmile Group, LLC | 10%+ Owner | 2,165,708 | $30.06M |
| Jeremy Green | 10%+ Owner | 2,165,708 | $30.06M |
| David Kroin | 10%+ Owner | 1,957,138 | $27.17M |
| Frazier Life Sciences XI, L.P. | 10%+ Owner | 1,824,541 | $25.32M |
| Sanofi | 10%+ Owner | 1,082,855 | $15.03M |
| Colin Walsh | Director | 83,565 | $1.16M |
| GOLDMAN SACHS GROUP INC | — | 62,474 | $867.14K |
| West Street Life Sciences I, L.P. | — | 62,374 | $865.75K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ATTO quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.